Biosensor technology company ivWatch and Marathon Medical have signed a multi-year distribution agreement for the former’s patient monitoring technology in the US.
ivWatch’s monitoring technology safeguards patients by detecting early IV infiltration and extravasation, reducing unpredictable complications.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the deal, Marathon Medical will supply the ivWatch patient monitoring system to Indian Health Service hospitals and clinics, VA hospitals and clinics and other federal agencies.
Through this partnership, ivWatch products will be integrated into Marathon’s FSS/GSA contracts, thereby enhancing their visibility and granting direct access to ivWatch technology for the advancement of IV therapy.
ivWatch president and CEO Gary Warren said: “ivWatch and Marathon Medical share the same belief in the importance of standing up, speaking up and fighting for better patient safety and that determination combined with our shared employee cultures of empathy and selflessness define our partnership.”
ivWatch products utilise a predictive algorithm and multi-spectral light to detect extravasations, drawing from 20 years of research and over 30 clinical studies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThey detect extravasations at the earliest fluid leakage onset outside of the vein.
Any extravasation represents a medication dosing error that can result in serious consequences, including scarring, nerve damage, skin necrosis and, in the most severe cases, amputation.
Both entities will work together to offer clinical vascular access education services, help facilities assess how the technology fits into their operations and provide product implementation support.
